KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.90

Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial.

Celine Bourgier, Caroline Mollevi, Didier Cowen, Florence Castan, Claire Lemanski, Sophie Gourgou, Sofia Rivera, Alain Labib, Karine Peignaux, Magali Le Blanc-Onfroy, Ahmed Benyoucef, Alice Mege, Zineb Douadi-Gaci, Severine Racadot, Igor Latorzeff, Ulrike Schick, Stephane Jacquot, Carole Massabeau, Philippe Guilbert, Julien Geffrelot, Stephen Ellis, Isabelle Lecouillard, Christel Breton-Callu, Agnès Richard-Tallet, Fatiha Boulbair, Aurélie Belliere, Nicolas Magné, Yazid Belkacémi, Françoise Bons, Pascal Fenoglietto, David Azria

Int J Radiat Oncol Biol Phys 124(1) 109-121

PMID40752655
PMCID-
DOI10.1016/j.ijrobp.2025.07.1442
发表日期2025-08-02
入排依据:The record describes a Phase III randomized trial in breast DCIS with a time-to-event primary endpoint. However, the intervention is radiation therapy (a non-drug technique), and the reported results are for secondary endpoints (toxicity and quality of life). The eligibility criteria require a drug-containing intervention and an original report of the primary or key secondary efficacy endpoint. This report does not meet the drug intervention criterion.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: In ductal carcinoma in situ, whole breast radiation therapy (WBRT) reduces local recurrence rates, but ipsilateral breast events at 10 years were observed in 15% to 19% of 50-year-old patients. The BONBIS trial (NCT00907868) assessed the effect of an additional localized radiation boost on local recurrence-free survival (primary endpoint). METHODS AND MATERIALS: This large multicenter (n = 53), randomized, open-label phase 3 trial was conducted from November 2008 to July 2014. In total, 2004 patients with complete ductal carcinoma in situ resection underwent postsurgery WBRT followed or not by a 16-Gy boost in the tumor bed. Only late radiation therapy-induced toxicity occurrence (National Cancer Institute Common Terminology Criteria for Adverse Events v3.0), health-related quality of life European Organisation for Research and Treatment Of Cancer (EORTC) Quality of life Cancer Patients (QLQ-C30) v3.0 and EORTC Quality of life Breast Cancer Patients (QLQ-BR23), and potential predictive factors of breast subcutaneous fibrosis (BSCF) (ie, secondary endpoints) will be reported here because the primary endpoint has not been reached yet. RESULTS: After a median follow-up of 66.9 months (95% CI, 65.1-67.8), grade ≥2 BSCF was observed in 4.9% of patients (7.0% in the WBRT + boost vs 2.8% in the WBRT arm; P < .001). Grade ≥2 acute and late toxicities were positively correlated (P = .005). Grade ≥2 BSCF was correlated with the boost (odds ratio = 2.6; 95% CI, 1.62-4.30) and breast clinical target volume ≥500 cm3 (odds ratio = 1.6; 95% CI, 1.01-2.51). Among the QLQ-C30 and QLQ-BR23 domain and symptom scores, only the breast symptom scores exhibited an arm-by-time interaction effect (P = .001) with a greater long-term breast symptom experience in the WBRT + boost arm. Time to first deterioration analysis showed a statically significant deterioration for body image in the WBRT + boost arm (hazard ratio = 1.19; 95% CI, 1.00-1.41). CONCLUSIONS: The boost significantly increased grade ≥2 BSCF occurrence and persistent breast symptoms.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。